세계의 심혈관 치료제 시장 - 규모, 점유율, 성장 분석 : 약제 유형별, 질환 적응증별, 투여 경로별, 유통 채널별, 지역별 산업 예측(2024-2031년)

Global Cardiovascular Drugs Market size was valued at USD 148.3 billion in 2022 and is poised to grow from USD 154.3 billion in 2023 to USD 209.0 billion by 2031, growing at a CAGR of 3.9% during the forecast period (2024-2031).

The cardiovascular drug market is experiencing significant growth driven by increasing hypertension prevalence and the rising incidence of cardiovascular disorders, particularly among young professionals in developing nations with demanding work schedules. Sedentary lifestyles and poor dietary habits contribute to escalating cardiovascular disease rates, prompting a surge in related drug sales. Additionally, the demographic trend shows a disturbing decrease in the age of onset for these disorders, further propelling market demand. While developed countries benefit from higher disposable incomes that enhance drug accessibility, challenges persist in developing regions due to financial constraints and limited awareness of healthcare resources. Moreover, stringent drug approval processes and potential side effects serve as barriers to market expansion, presenting complexities in addressing the growing cardiovascular health crisis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiovascular Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiovascular Drugs Market Segmental Analysis

Global Cardiovascular Drugs Market is segmented by Drug Type, Disease Indication, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs, Others. Based on Disease Indication, the market is segmented into Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral, Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiovascular Drugs Market

One of the key drivers propelling the Global Cardiovascular Drugs market is the rising prevalence of cardiovascular diseases, which is significantly influenced by sedentary lifestyles. The World Health Organization (WHO) notes that between 60% to 85% of the global population is inactive, with the Centers for Disease Control and Prevention (CDC) reporting approximately 31 million Americans aged 50 and older engaging in minimal physical activity. Additionally, only about 25% of adults in the U.S. meet the recommended levels of exercise. This alarming trend of inactivity contributes to the growing incidence of cardiovascular conditions, subsequently driving demand for cardiovascular medications and treatments.

Restraints in the Global Cardiovascular Drugs Market

One of the key restraints affecting the global cardiovascular drugs market is the shortage of skilled professionals, which hinders effective drug development and patient care. Additionally, the stringent drug approval processes imposed by regulatory authorities can delay the introduction of new therapies, further constraining market growth. Furthermore, the potential side effects associated with certain cardiovascular medications may deter both healthcare providers and patients from utilizing these treatments, leading to limited adoption. These factors collectively create significant challenges that impact the overall expansion and accessibility of cardiovascular drugs in the market.

Market Trends of the Global Cardiovascular Drugs Market

The Global Cardiovascular Drugs market is experiencing robust growth driven by rising obesity and high cholesterol levels, which significantly elevate cardiovascular disease risks. The demand for emergency medications in hospitals highlights a vital growth area, with many patients requiring long-term management for chronic conditions, ensuring consistent revenue streams. The escalating prevalence of hypertension has further fueled the need for blood thinners and antihypertensive drugs. Additionally, increasing life expectancy among the elderly and a concerning rise in cardiovascular diseases among children are propelling market expansion. The chronic nature of hypertensive medications also contributes to sustained demand, reinforcing the market's positive trajectory.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Technological Advancement
• Regulatory Landscape
• Value Chain Analysis
• Patent Analysis
• Case Study Analysis
• Patent Analysis
• Pricing Analysis
• Pipeline Analysis
• Disease Epidemiology
• PESTEL Analysis
• Macro-Economic Indicators
• Market Attractiveness Index

Global Cardiovascular Drugs Market Size by Drug Type & CAGR (2024-2031)

• Market Overview
• Antihypertensive
• Anticoagulants
• Antihyperlipidemic
• Antiplatelet Drugs
• Others

Global Cardiovascular Drugs Market Size by Disease Indication & CAGR (2024-2031)

• Market Overview
• Hypertension
• Coronary Artery Disease
• Hyperlipidaemia
• Arrhythmia
• Others

Global Cardiovascular Drugs Market Size by Route of Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Parenteral
• Others

Global Cardiovascular Drugs Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Cardiovascular Drugs Market Size & CAGR (2024-2031)

• North America (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMGen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Co Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation